Condition: Superficial Bladder Cancer · Bladder Cancer · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.
This description comes directly from the study's public registry record.
M. J. Remmelink, MD · 0204441376 · m.j.remmelink@amsterdamumc.nl
J. W. Wilmink, MD, PhD · 0205665983 · j.w.wilmink@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| RadboudUMC | Nijmegen, Gelderland, Netherlands | Not Yet Recruiting |
| Sint Franciscus Gasthuis | Rotterdam, South Holland, Netherlands | Not Yet Recruiting |
| Academic Medical Center | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03379909